405
Participants
Start Date
January 3, 2014
Primary Completion Date
December 29, 2015
Study Completion Date
March 14, 2017
Blinatumomab
Blinatumomab is administered as a continuous intravenous infusion (CIV).
Standard of Care Chemotherapy
"* FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen (e.g. idarubicin 10 mg/m² days 1 \& 3; fludarabine 30 mg/m² days 1-5; cytarabine arabinoside 2 g/m² days 1-5). Patients \> 60 years: Idarubicin 5 mg/m² day 1 \& 3; fludarabine 20 mg/m² day 1-5; cytarabine arabinoside 1 g/m² day 1-5~* HiDAC (high-dose cytarabine arabinoside) - based regimen ≥1 g/m²/day ± anthracycline and/or in combination with other drugs such as native Escherichia coli asparaginase, polyethylene glycol linked to asparaginase (PEG-asparaginase), vinca alkaloids, steroids, etoposide or alkylating agents~* High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours) in combination with native E. coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents.~* Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days."
Research Site, Dublin
Research Site, Vienna
Research Site, Vienna
Research Site, Brussels
Research Site, Sofia
Research Site, Antwerp
Research Site, St Leonards
Research Site, Leuven
Research Site, Parkville
Research Site, Prahran
Research Site, Plovdiv
Research Site, Herston
Research Site, Wels
Research Site, Adelaide
Research Site, Salzburg
Research Site, Yvoir
Research Site, Murdoch
Research Site, Bruges
Research Site, Ghent
Research Site, Taipei
Research Site, New York
Research Site, Torino
Research Site, Athens
Research Site, Athens
Research Site, Berlin
Research Site, Baltimore
Research Site, Kiel
Research Site, Bergamo
Research Site, Pátrai
Research Site, Durham
Research Site, Madrid
Research Site, Novara
Research Site, Greenville
Research Site, Venezia
Research Site, Atlanta
Research Site, Toulouse
Research Site, Haifa
Research Site, Oviedo
Research Site, Pessac
Research Site, Istanbul
Research Site, Izmir
Research Site, Salamanca
Research Site, Verona
Research Site, Nashville
Research Site, Bologna
Research Site, Taichung
Research Site, Nantes
Research Site, Ioannina
Research Site, Essen
Research Site, Valencia
Research Site, Münster
Research Site, Petah Tikva
Research Site, Changhua
Research Site, Florence
Research Site, Cologne
Research Site, Tel Litwinsky
Research Site, Milwaukee
Research Site, Rochester
Research Site, Thessaloniki
Research Site, Frankfurt am Main
Research Site, Chicago
Research Site, St Louis
Research Site, Tel Aviv
Research Site, Monterrey
Research Site, Heidelberg
Research Site, Pierre-Bénite
Research Site, Bari
Research Site, Tainan City
Research Site, Tübingen
Research Site, Paris
Research Site, Houston
Research Site, Le Chesnay
Research Site, Freiburg im Breisgau
Research Site, Napoli
Research Site, München
Research Site, Ulm
Research Site, Los Angeles
Research Site, Palermo
Research Site, Duarte
Research Site, Jerusalem
Research Site, Jerusalem
Research Site, Créteil
Research Site, San Francisco
Research Site, Würzburg
Research Site, Moscow
Research Site, Petrozavodsk
Research Site, Saratov
Research Site, Nizhny Novgorod
Research Site, Boston
Research Site, Boston
Research Site, Toronto
Research Site, Montreal
Research Site, Brno
Research Site, Hradec Králové
Research Site, Prague
Research Site, Prague
Research Site, Leipzig
Research Site, Roma
Research Site, Roma
Research Site, Mexico City
Research Site, Lublin
Research Site, Warsaw
Research Site, Warsaw
Research Site, Wroclaw
Research Site, Busan
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Badalona
Research Site, Adana
Research Site, Ankara
Research Site, Bristol
Research Site, London
Research Site, Oxford
Research Site, Sheffield
Research Site, Southampton
Research Site, Sutton
Lead Sponsor
Amgen
INDUSTRY